199 related articles for article (PubMed ID: 16213181)
1. Criteria for selection of HIV vaccine candidates--general principles.
Ensoli B
Microbes Infect; 2005 Nov; 7(14):1433-5. PubMed ID: 16213181
[TBL] [Abstract][Full Text] [Related]
2. The rationale behind a vaccine based on multiple HIV antigens.
Rollman E; Bråve A; Boberg A; Gudmundsdotter L; Engström G; Isaguliants M; Ljungberg K; Lundgren B; Blomberg P; Hinkula J; Hejdeman B; Sandström E; Liu M; Wahren B
Microbes Infect; 2005 Nov; 7(14):1414-23. PubMed ID: 16257558
[TBL] [Abstract][Full Text] [Related]
3. Vaccines based on Nef and on Nef/DeltaV2 Env.
Erfle V; Goebel FD; Guzman CA; Le Grand R
Microbes Infect; 2005 Nov; 7(14):1400-4. PubMed ID: 16243564
[TBL] [Abstract][Full Text] [Related]
4. Gene combination raises broad human immunodeficiency virus-specific cytotoxicity.
Calarota SA; Kjerrström A; Islam KB; Wahren B
Hum Gene Ther; 2001 Sep; 12(13):1623-37. PubMed ID: 11535166
[TBL] [Abstract][Full Text] [Related]
5. Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH.
Malm M; Rollman E; Ustav M; Hinkula J; Krohn K; Wahren B; Blazevic V
Viral Immunol; 2005; 18(4):678-88. PubMed ID: 16359234
[TBL] [Abstract][Full Text] [Related]
6. Vaccines based on the native HIV Tat protein and on the combination of Tat and the structural HIV protein variant DeltaV2 Env.
Ensoli B; Cafaro A; Caputo A; Fiorelli V; Ensoli F; Gavioli R; Ferrantelli F; Cara A; Titti F; Magnani M
Microbes Infect; 2005 Nov; 7(14):1392-9. PubMed ID: 16243561
[TBL] [Abstract][Full Text] [Related]
7. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants.
Fischer W; Perkins S; Theiler J; Bhattacharya T; Yusim K; Funkhouser R; Kuiken C; Haynes B; Letvin NL; Walker BD; Hahn BH; Korber BT
Nat Med; 2007 Jan; 13(1):100-6. PubMed ID: 17187074
[TBL] [Abstract][Full Text] [Related]
8. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.
Gómez CE; Nájera JL; Jiménez V; Bieler K; Wild J; Kostic L; Heidari S; Chen M; Frachette MJ; Pantaleo G; Wolf H; Liljeström P; Wagner R; Esteban M
Vaccine; 2007 Mar; 25(11):1969-92. PubMed ID: 17224219
[TBL] [Abstract][Full Text] [Related]
9. A DNA HIV-1 vaccine based on a fusion gene expressing non-structural and structural genes of consensus sequence of the A-C subtypes and the ancestor sequence of the F-H subtypes. Preclinical and clinical studies.
Krohn K; Stanescu I; Blazevic V; Vesikari T; Ranki A; Ustav M
Microbes Infect; 2005 Nov; 7(14):1405-13. PubMed ID: 16257560
[TBL] [Abstract][Full Text] [Related]
10. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.
Letvin NL; Huang Y; Chakrabarti BK; Xu L; Seaman MS; Beaudry K; Korioth-Schmitz B; Yu F; Rohne D; Martin KL; Miura A; Kong WP; Yang ZY; Gelman RS; Golubeva OG; Montefiori DC; Mascola JR; Nabel GJ
J Virol; 2004 Jul; 78(14):7490-7. PubMed ID: 15220422
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine.
Catanzaro AT; Roederer M; Koup RA; Bailer RT; Enama ME; Nason MC; Martin JE; Rucker S; Andrews CA; Gomez PL; Mascola JR; Nabel GJ; Graham BS;
Vaccine; 2007 May; 25(20):4085-92. PubMed ID: 17391815
[TBL] [Abstract][Full Text] [Related]
12. Induction of human immunodeficiency virus type-1-specific immunity with a novel gene transport unit (GTU)-MultiHIV DNA vaccine.
Blazevic V; Männik A; Malm M; Sikut R; Valtavaara M; Toots U; Ustav M; Krohn K
AIDS Res Hum Retroviruses; 2006 Jul; 22(7):667-77. PubMed ID: 16831091
[TBL] [Abstract][Full Text] [Related]
13. Development of V2-deleted trimeric envelope vaccine candidates from human immunodeficiency virus type 1 (HIV-1) subtypes B and C.
Barnett SW; Srivastava IK; Ulmer JB; Donnelly JJ; Rappuoli R
Microbes Infect; 2005 Nov; 7(14):1386-91. PubMed ID: 16275150
[TBL] [Abstract][Full Text] [Related]
14. Human immunodeficiency virus type 2 DNA vaccine provides partial protection from acute baboon infection.
Locher CP; Witt SA; Ashlock BM; Polacino P; Hu SL; Shiboski S; Schmidt AM; Agy MB; Anderson DM; Staprans SI; zur Megede J; Levy JA
Vaccine; 2004 Jun; 22(17-18):2261-72. PubMed ID: 15149785
[TBL] [Abstract][Full Text] [Related]
15. Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization.
Ramakrishna L; Anand KK; Mohankumar KM; Ranga U
J Virol; 2004 Sep; 78(17):9174-89. PubMed ID: 15308713
[TBL] [Abstract][Full Text] [Related]
16. Reconstruction and function of ancestral center-of-tree human immunodeficiency virus type 1 proteins.
Rolland M; Jensen MA; Nickle DC; Yan J; Learn GH; Heath L; Weiner D; Mullins JI
J Virol; 2007 Aug; 81(16):8507-14. PubMed ID: 17537854
[TBL] [Abstract][Full Text] [Related]
17. Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes.
Hinkula J; Svanholm C; Schwartz S; Lundholm P; Brytting M; Engström G; Benthin R; Glaser H; Sutter G; Kohleisen B; Erfle V; Okuda K; Wigzell H; Wahren B
J Virol; 1997 Jul; 71(7):5528-39. PubMed ID: 9188627
[TBL] [Abstract][Full Text] [Related]
18. Design, construction, and characterization of a dual-promoter multigenic DNA vaccine directed against an HIV-1 subtype C/B' recombinant.
Huang Y; Chen Z; Zhang W; Gurner D; Song Y; Gardiner DF; Ho DD
J Acquir Immune Defic Syndr; 2008 Apr; 47(4):403-11. PubMed ID: 18209683
[TBL] [Abstract][Full Text] [Related]
19. Building collaborative networks for HIV/AIDS vaccine development: the AVIP experience.
Ferrantelli F; Buttò S; Cafaro A; Wahren B; Ensoli B
Springer Semin Immunopathol; 2006 Nov; 28(3):289-301. PubMed ID: 16983452
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity testing of a novel engineered HIV-1 envelope gp140 DNA vaccine construct.
Kumar S; Yan J; Muthumani K; Ramanathan MP; Yoon H; Pavlakis GN; Felber BK; Sidhu M; Boyer JD; Weiner DB
DNA Cell Biol; 2006 Jul; 25(7):383-92. PubMed ID: 16848679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
